Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
06 Novembro 2023 - 10:05AM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
clinical-stage biopharmaceutical company, focused on identifying,
developing and commercializing treatments in high unmet need areas
involving rare diseases and multi-drug resistant (MDR) bacterial
infections, today announced that it will host a conference call and
live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to
report its third quarter 2023 financial results and provide an
update on its business and pipeline.
To access the call, please dial 1-877-704-4453
(domestic) or 1-201-389-0920 (international) and refer to
conference ID 13741831, or click on this link and
request a return call. The audio webcast can be accessed on the
"Events and Presentations" page under the “Connect” tab of the
Company's website at www.sperotherapeutics.com.
The archived webcast will also be available on Spero's website for
30 days following the call.
About Spero TherapeuticsSpero
Therapeutics, headquartered in Cambridge, Massachusetts, is a
multi-asset, clinical-stage biopharmaceutical company focused on
identifying, developing, and commercializing novel treatments for
bacterial infections, including multi-drug resistant bacterial
infections and rare diseases.
- Spero Therapeutics is developing
SPR720 as a novel oral therapy candidate for the treatment of a
rare, orphan pulmonary disease caused by non-tuberculous
mycobacterial infections.
- Tebipenem HBr is an investigational
drug in the United States being developed for the treatment of
complicated urinary tract infection (cUTI), including
pyelonephritis, caused by certain bacteria, in adult patients who
have limited treatment options; tebipenem HBr is not U.S. Food and
Drug Administration (FDA)-approved.
- Spero Therapeutics also has an
IV-administered next generation polymyxin product candidate,
SPR206, developed from its potentiator platform, which is in
development to treat MDR Gram-negative infections in the hospital
setting.
For more information, visit
https://sperotherapeutics.com.
Investor Relations Contact: Ted
JenkinsVice President, Investor Relations and Strategic
FinanceIR@sperotherapeutics.com (617) 798-4039
Media Inquiries: Lora Grassilli, Health Media
RelationsZeno Grouplora.grassilli@zenogroup.com646-932-3735
Spero Therapeutics (NASDAQ:SPRO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Spero Therapeutics (NASDAQ:SPRO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024